Gold nanoparticles offered to ALS patients in expanded access program
NCT ID NCT05281484
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides CNM-Au8, a suspension of gold nanocrystals, to up to 300 people with ALS. The main goal is to give access to the drug and monitor safety, not to test if it works. Participants must have a confirmed ALS diagnosis and be at least 18 years old.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CNM-Au8 (nanocrystalline gold suspension)
What this could lead to
If successful, this could provide a treatment option for ALS patients, potentially slowing disease progression.
What could go wrong
This is an expanded access program, not a formal trial, so it won't prove effectiveness. Safety is the main focus, and benefits are uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barrow Neurological Institute
Phoenix, Arizona, 85013, United States
-
DUKE University Medical Center (Enrollment is full, not recruiting)
Durham, North Carolina, 27705, United States
-
Henry Ford Health Systems (Enrollment is full, not recruiting)
Detroit, Michigan, 48322, United States
-
Hospital for Special Care (Enrollment is full, not recruiting)
New Britain, Connecticut, 06053, United States
-
Jefferson Hospital (Enrollment is full, not recruiting)
Philadelphia, Pennsylvania, 19107, United States
-
Massachusetts General Hospital (Enrollment is full, not recruiting)
Boston, Massachusetts, 02114, United States
-
Northwestern (Enrollment is full, not recruiting)
Chicago, Illinois, 60611, United States
-
Nova Southeastern University
Davie, Florida, 33314, United States
-
Penn State Health (Enrollment is full, not recruiting)
Hershey, Pennsylvania, 17033, United States
-
Providence Health (Enrollment is full, not recruiting)
Portland, Oregon, 97225, United States
-
Sutter Health (Enrollment is full, not recruiting)
San Francisco, California, 94107, United States
-
Texas Neurology
Dallas, Texas, 75206, United States
-
UC Irvine
Orange, California, 92868, United States
-
University of Kansas (Enrollment is full, not recruiting)
Fairway, Kansas, 66205, United States
-
University of Nebraska Medical Center (Enrollment is full, not recruiting)
Omaha, Nebraska, 68198, United States
-
University of Washington
Seattle, Washington, 98195, United States